ライフサイエンスコーパス: disease-free survival rate

1 r reduced responses to therapy and decreased disease-free survival rate.

2 axillary nodes have a significantly improved disease-free survival rate.

3 Patients with stage III disease, had a 60% disease-free survival rate.

4 of local and distant recurrence, and 5-year disease-free survival rates.

5 with 5-year overall (54% v 14%, P = .07) and disease-free survival rates (32% v 18%, P = .039) higher

6 , local recurrence (4% vs 5%, P = 0.98), and disease-free survival rate (72% vs 68%, P = 0.63) betwee

7 e of T+29C polymorphism had a reduced 5-year disease-free survival rate (75.6% for T/C, and 78.2% for

8 The 3-year overall and disease-free survival rates after laparoscopic liver res

9 The 5-year overall and disease-free survival rates after laparoscopic liver res

10 The estimated 1-year and 2-year disease-free survival rates are 62% and 46%, respectivel

11 The estimated disease-free survival rates are approximately equivalent

12 lete remissions providing 5-year overall and disease-free survival rates as high as those reported fo

13 The estimated disease-free survival rate at 10 years was 98.7%.

14 median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the t

15 Disease-free survival rates at 5 and 10 years were 34% a

16 The estimated disease-free survival rates at 5 years were 75% among pa

17 RV-infected mice had significantly increased disease-free survival rate compared to WT RRV-infected B

18 (+/- 4%) 5-year and an 84% (+/- 12%) 10-year disease-free survival rate, compared with a 5-year disea

19 s with resected gastric cancer with a 2-year disease-free survival rate (DFS) of 52%.

20 The disease-free survival rate difference was 0.3% (favoring

21 The 2-year disease-free survival rate (excluding metachronous contr

22 Tissue microarray analysis showed that the disease-free survival rate for patients with high-expres

23 The median survival and disease-free survival rate for the patients with residua

24 melanoma, the mean (+/-SE) estimated 5-year disease-free survival rate for the population was 78.3+/

25 short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rat

26 The median survival and disease-free survival rates for all patients were 25.8 m

27 The disease-free survival rates for HCCA and PCCA were 85% (

28 One-, 3-, and 5-year disease-free survival rates for the entire population we

29 th anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/

30 The 24-month disease-free survival rate from time of CR was 90.9% in

31 The 5-year overall and disease-free survival rates from transplantation were 77

32 in high complete remission rates, long-term disease-free survival rates have remained disappointingl

33 The 8-year disease-free survival rate in AJCC stage I patients whos

34 verall and after induction chemotherapy) and disease-free survival rate in patients who received mult

35 Chemotherapy improves long-term disease-free survival rates in high-risk patients with r

36 Overall and disease-free survival rates in the good risk group were

37 e-free survival rate, compared with a 5-year disease-free survival rate of 29% (+/- 30%) for those wh

38 We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and

39 cal margin, and low CEA levels have a 5-year disease-free survival rate of more than 30%.

40 form of surgery offers a 5-year biochemical disease-free survival rate of no better than 50%.

41 ted significant inverse correlation with the disease-free survival rate of patients and emerged as an

42 The 5-year disease-free survival rate of the definitive resection (

43 at AYA patients have improved outcomes, with disease-free survival rates of 60% to 70%, when treated

44 sponse rates of 85% or greater and long-term disease-free survival rates of 70% or greater.

45 deaths in the observation group, with 5-year disease-free survival rates of 75% and 58% (P =.0003 una

46 rs, the cross-over strategy yielded absolute disease-free survival rates of 83.7% and 67.6% for node-

47 rgroup trial 0116, prolonged the overall and disease-free survival rates of patients after a curative

48 Disease-free survival rates of patients with MMR-deficie

49 a failure (after > or = 1 year), the 5-year disease-free survival rate on the adjuvant goserelin arm

50 ata have shown no significant differences in disease-free survival rates or overall survival rates be

51 its independent significance for overall and disease-free survival rates (P = 0.045 and 0.006, respec

52 D had a significantly lower 3-year Parkinson disease-free survival rate than comparison subjects (P <

53 ontrol rates to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respe

54 The 3-year disease-free survival rate was 15% (95% CI, 9% to 24%).

55 rgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%.

56 The 3-year disease-free survival rate was 40%.

57 The 5-year disease-free survival rate was 44%.

58 hereas in patients with melastatin loss, the disease-free survival rate was 51% +/- 8%.

59 patients with stage III disease, the 5-year disease-free survival rate was 56% for stage III patient

60 The 5-year disease-free survival rate was 60% (95% confidence inter

61 The 2-year disease-free survival rate was 66%, and median disease-f

62 al 5-year overall survival rate was 81%; the disease-free survival rate was 75% and the local recurre

63 n stage I patients with melastatin loss, the disease-free survival rate was 77% +/- 15% (median +/- S

64 e patients (19%) had relapsed, the actuarial disease-free survival rate was 78% (95% confidence inter

65 The 5-year disease-free survival rate was 88%.

66 fusely expressed melastatin mRNA, the 8-year disease-free survival rate was 90% +/- 7%, whereas in pa

67 The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2)

68 The 5-year disease-free survival rate was 95% (95% confidence inter

69 The 5-year disease-free survival rate was four-fold greater for pat

70 No RT (83%) patients (p = 0.10), whereas the disease-free survival rate was significantly worse for P

71 Five-year disease-free survival rates were 39% in the FU plus LV a

72 Overall 5-year and disease-free survival rates were 51% and 46%, respective

73 The 1- and 3-year disease-free survival rates were 64.5% and 19%, respecti

74 -Meier estimated 5-year overall survival and disease-free survival rates were 66% and 53%, respective

75 of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respective

76 The local recurrence and 5-year disease-free survival rates were 7% and 78%, respectivel

77 The estimated 2-year overall survival and disease-free survival rates were 71.6% and 53.5%, respec

78 Respective 5-year disease-free survival rates were 74% and 24% (P =.0001).

79 Disease-free survival rates were 74.8% in the laparoscop

80 The actuarial 7-year disease-free survival rates were 81% and 87% (P = 0.764)

81 ctively (p = 0.02); the corresponding 5-year disease-free survival rates were 81.9%, 78.1%, and 76.6%

82 urrence rate was 4% and overall survival and disease-free survival rates were 83% and 70% at 5 years,

83 The 5-year disease-free survival rates were 87% in patients with pr

84 a median follow-up of 61 months, the 5-year disease-free survival rates were 87% in patients without

85 The 1-, 3-, and 5-year disease-free survival rates were as follows: 77%, 41%, a

86 However, the 10-y disease-free survival rates were better for the SLNB gro

87 Local recurrence rates were very low and disease-free survival rates were correspondingly high in

88 homas (884 patients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% an

89 The 5-year overall and disease-free survival rates were significantly higher in

90 Mean (+/- SE) 10-year disease-free survival rates were significantly improved

91 36 months, 3-year overall survival (OS) and disease-free survival rates were significantly lower in

92 The overall survival and disease-free survival rates were significantly worse for

93 BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (

94 ear OS of approximately 85%; however, 5-year disease-free survival rates with S plus CT were 78% (T1-

95 n is associated with an actuarial 51% 5-year disease-free survival rate, with a median follow-up time